Research Participants

Subjects come first for the BRANY Institutional Review Board (IRB). We are dedicated to protecting the rights and ensuring the welfare of all human research subjects, as evidenced by our commitment to ethical research and rigorous research oversight.

This section of our website provides current and potential research participants with useful information about participating in clinical trials, the protections they are entitled to, and a method to provide feedback and concerns about specific clinical trials.

 


Search Trials


Our Newest Trials

Atezolizumab In Combination With Cabozantinib

Subjects with Solid Tumors

High-Risk Non-Muscle-Invasive Bladder Cancer

Receptor 2 negative (HR+/HER2-) breast cancer – Astra Zeneca

Metastatic Cervical Cancer

Advanced and Recurrent Endometrial Cancer (DUO-E)

HER2-Positive Gastric or Gastroesophageal Junction Cancer

ROSY-O

TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (C/SLL) or Non-Hodgkin Lymphoma (NHL)